Global Neurometabolic Disorders Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Neurometabolic Disorders Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Gaucher’s Disease
  • 1.4.3 Fabry Disease
  • 1.4.4 Pompe Disease
  • 1.4.5 Mucopolysaccharidosis VI
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global Neurometabolic Disorders Market Share by Application (2019-2025)
  • 1.5.2 Oral
  • 1.5.3 Parenteral
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Neurometabolic Disorders Market Size
• 2.2 Neurometabolic Disorders Growth Trends by Regions
  • 2.2.1 Neurometabolic Disorders Market Size by Regions (2019-2025)
  • 2.2.2 Neurometabolic Disorders Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Neurometabolic Disorders Market Size by by Players
  • 3.1.1 Global Neurometabolic Disorders Revenue by by Players (2014-2019)
  • 3.1.2 Global Neurometabolic Disorders Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
• 3.2 Neurometabolic Disorders Key Players Head office and Area Served
• 3.3 Key Players Neurometabolic Disorders Product/Solution/Service
• 3.4 Date of Enter into Neurometabolic Disorders Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Neurometabolic Disorders Market Size by Type (2014-2019)
• 4.2 Global Neurometabolic Disorders Market Size by Application (2014-2019)

5 North America

• 5.1 North America Neurometabolic Disorders Market Size (2014-2019)
• 5.2 Neurometabolic Disorders Key Players in North America
• 5.3 North America Neurometabolic Disorders Market Size by Type
• 5.4 North America Neurometabolic Disorders Market Size by Application

6 Europe

• 6.1 Europe Neurometabolic Disorders Market Size (2014-2019)
• 6.2 Neurometabolic Disorders Key Players in Europe
• 6.3 Europe Neurometabolic Disorders Market Size by Type
• 6.4 Europe Neurometabolic Disorders Market Size by Application

7 China

• 7.1 China Neurometabolic Disorders Market Size (2014-2019)
• 7.2 Neurometabolic Disorders Key Players in China
• 7.3 China Neurometabolic Disorders Market Size by Type
• 7.4 China Neurometabolic Disorders Market Size by Application

8 Japan

• 8.1 Japan Neurometabolic Disorders Market Size (2014-2019)
• 8.2 Neurometabolic Disorders Key Players in Japan
• 8.3 Japan Neurometabolic Disorders Market Size by Type
• 8.4 Japan Neurometabolic Disorders Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Neurometabolic Disorders Market Size (2014-2019)
• 9.2 Neurometabolic Disorders Key Players in Southeast Asia
• 9.3 Southeast Asia Neurometabolic Disorders Market Size by Type
• 9.4 Southeast Asia Neurometabolic Disorders Market Size by Application

10 India

• 10.1 India Neurometabolic Disorders Market Size (2014-2019)
• 10.2 Neurometabolic Disorders Key Players in India
• 10.3 India Neurometabolic Disorders Market Size by Type
• 10.4 India Neurometabolic Disorders Market Size by Application

11 Central & South America

• 11.1 Central & South America Neurometabolic Disorders Market Size (2014-2019)
• 11.2 Neurometabolic Disorders Key Players in Central & South America
• 11.3 Central & South America Neurometabolic Disorders Market Size by Type
• 11.4 Central & South America Neurometabolic Disorders Market Size by Application

12 International Players Profiles

• 12.1 Amicus Therapeutics
  • 12.1.1 Amicus Therapeutics Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Neurometabolic Disorders Introduction
  • 12.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2014-2019))
  • 12.1.5 Amicus Therapeutics Recent Development
• 12.2 ISU Abxis
  • 12.2.1 ISU Abxis Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Neurometabolic Disorders Introduction
  • 12.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2014-2019)
  • 12.2.5 ISU Abxis Recent Development
• 12.3 JCR Pharmaceuticals
  • 12.3.1 JCR Pharmaceuticals Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Neurometabolic Disorders Introduction
  • 12.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2014-2019)
  • 12.3.5 JCR Pharmaceuticals Recent Development
• 12.4 Biosidus
  • 12.4.1 Biosidus Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Neurometabolic Disorders Introduction
  • 12.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2014-2019)
  • 12.4.5 Biosidus Recent Development
• 12.5 Greenovation Biotech
  • 12.5.1 Greenovation Biotech Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Neurometabolic Disorders Introduction
  • 12.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2014-2019)
  • 12.5.5 Greenovation Biotech Recent Development
• 12.6 UAB Proforma
  • 12.6.1 UAB Proforma Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Neurometabolic Disorders Introduction
  • 12.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2014-2019)
  • 12.6.5 UAB Proforma Recent Development
• 12.7 Dong-A Socio Group
  • 12.7.1 Dong-A Socio Group Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Neurometabolic Disorders Introduction
  • 12.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2014-2019)
  • 12.7.5 Dong-A Socio Group Recent Development
• 12.8 ExSAR Corporation
  • 12.8.1 ExSAR Corporation Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Neurometabolic Disorders Introduction
  • 12.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2014-2019)
  • 12.8.5 ExSAR Corporation Recent Development
• 12.9 Lixte Biotechnology
  • 12.9.1 Lixte Biotechnology Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Neurometabolic Disorders Introduction
  • 12.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2014-2019)
  • 12.9.5 Lixte Biotechnology Recent Development
• 12.10 Neuraltus Pharmaceuticals
  • 12.10.1 Neuraltus Pharmaceuticals Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Neurometabolic Disorders Introduction
  • 12.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2014-2019)
  • 12.10.5 Neuraltus Pharmaceuticals Recent Development
• 12.11 Protalix
• 12.12 Pharming Group
• 12.13 Protalix BioTherapeutics
• 12.14 Amicus
• 12.15 Biomarin
• 12.16 Genzyme
• 12.17 Shire
• 12.18 Greencross

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Product (2019-2025)
• 13.2 Market Size Forecast by Application (2019-2025)
• 13.3 Market Size Forecast by Regions
• 13.4 North America
• 13.5 Europe
• 13.6 China
• 13.7 Japan
• 13.8 Southeast Asia
• 13.9 India
• 13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer